Jacobio Pharma Presented Preliminary Results from a Phase I Trial of Jab-8263 at ASH 2024 / Andrea Wang-Gillam, Bo Jiang, cancer, Chao Bi, Hongmei Jing,

FDA has approved RYBREVANT FASPRO™/ subcutaneous amivantamab with lazertinib as the first and only subcutaneous therapy available across all approved indications for EGFR-mutated NSCLC. 🧬 This approva...

Jacobio Pharma shares its significant yearly achievements for 2025, highlighting breakthroughs in KRAS-targeted therapies and clinical advancements.

Jacobio Pharma unveiled notable pre-clinical results of JAB-23E73, a pan-KRAS inhibitor, at the AACR-NCI-EORTC conference, highlighting its effectiveness.

Jacobio Pharma has signed a major deal with AstraZeneca for its Pan-KRAS inhibitor JAB-23E73, enhancing global cancer treatment efforts.

AstraZeneca pays $100M upfront for Jacobio Pharma's JAB-23E73 cancer drug rights outside China; could pay $1.9B in milestones. Drug is in Phase 1 trials in US and China.

The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next generation of cancer treatments. We spoke with Andrea Wang-Gillam, MD, PhD, of Jacobio Pharmaceuticals; Kiyean Nam, PhD, of Qurient; Sharanya Nag, PhD, of Memorial Sloan Kettering Cancer Center; and Giuseppina Carbone, MD, about their innovative strategies to inhibit KRAS, enhance antibody-drug conjugate efficacy, and tackle resistance. The post From the Bench, AACR D3 2026: Emerging Therapeutic Strategies to Inhibit KRAS, Enhance ADCs, and Tackle Resistance appeared first on American Association for Cancer Research (AACR).

KRAS Inhibitors Drugs Market KRAS Inhibitors companies working in the market are Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others (Albany, USA) In 2024, the United States held nearly 70% of the KRAS inhibitors market across the 7MM, driven by a high burden of KRAS-mutated cancers, especially NSCLC, which accounts for 46% of such cases in the region.

BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ — Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development and commercialisation rights outside of China, while Jacobio and AstraZeneca will jointly develop and commercialise JAB-23E73 in China. Under the terms of the […]

A deal with Jacobio is worth $100m up front.

Jacobio Pharma granted AstraZeneca exclusive global development and commercialization rights to its experimental pan-KRAS inhibitor JAB-23E73 in a licensing agreement announced December 21 with a potential total value of up to $2.015 billion. The Hong Kong-listed biotech firm detailed the agreement terms on December 21. Jacobio will receive a $100 million upfront payment. The company […]

AstraZeneca pays $100M upfront for Jacobio Pharma's JAB-23E73 cancer drug rights outside China; could pay $1.9B in milestones. Drug is in Phase 1 trials in US and China.

Jacobio is now conducting a Phase III study on glecirasib and sitneprofatib in first-line NSCLC, which could see it gain approval on home soil

Multiple biotech deals: Dianthus's $30M autoimmune deal, C4's $125M offering, Merck's Keytruda success, Oceanpine's Jacobio stake, Immunai-AstraZeneca partnership, BridGene's $28M raise

BEIJING (Jan 4): China’s rise in manufacturing has rarely been associated with drug discovery. That, quietly, is starting to change — giving “Made in China” a new chemistry. Recently, Chinese biotech innovator Jacobio Pharma reached an agreement to license an experimental cancer drug targeting a notoriously difficult genetic mutation to pharmaceutical giant AstraZeneca. The potentialRead More

Jacobio Pharma signs $2 billion license deal with AstraZeneca for cancer drug

Jacobio Pharma has joined forces with Oceanpine Capital to enhance its oncology pipeline, focusing on innovative cancer therapies and operational efficiency.

Jacobio Pharmaceuticals announces significant shareholding increase by executives, reflecting strong confidence in long-term growth and innovation.

Jacobio Pharma has announced robust interim results for 2025, highlighting significant revenue growth, reduced losses, and promising advancements in its pipeline of cancer therapies.

Jacobio Pharma has received approval for their Phase I/II clinical trial application for the BET inhibitor JAB-8263 aimed at treating autoimmune diseases.

Jacobio Pharma has announced its annual results for 2024, showcasing strong revenue growth and significant advancements in cancer treatment developments.

Jacobio Pharma has presented promising preliminary data on its BET inhibitor, JAB-8263, for myelofibrosis treatment at the 2024 ASH Annual Meeting.